Building a pipeline to discover and validate novel therapeutic targets and lead compounds for Alzheimer's disease

Biochemical Pharmacology

Volumn 88, Issue 4, 2014, Pages 617-630

  Bennett, David A ^a   Yu, Lei ^a   De Jager, Philip L ^b,c  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c BROAD INSTITUTE OF MIT AND HARVARD   (United States)

Author keywords

Alzheimer's disease; RNAi; Small molecule screen; Systems biology; Targeted proteomics

Indexed keywords

AMYLOID BETA PROTEIN; BETA SECRETASE; GAMMA SECRETASE; MESSENGER RNA; MICRORNA; TAR DNA BINDING PROTEIN;

AGING; ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; CEREBROVASCULAR DISEASE; COGNITION; COGNITIVE DEFECT; DNA FLANKING REGION; DNA METHYLATION; DRUG DEVELOPMENT; DRUG TARGETING; ENDOPHENOTYPE; FRONTOTEMPORAL DEMENTIA; GENETIC VARIABILITY; GENOTYPE; HIPPOCAMPAL SCLEROSIS; HISTONE ACETYLATION; HUMAN; LEWY BODY; MILD COGNITIVE IMPAIRMENT; NEUROFIBRILLARY TANGLE; NEUROPATHOLOGY; OXIDATIVE STRESS; PHASE 1 CLINICAL TRIAL (TOPIC); PLURIPOTENT STEM CELL; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEOMICS; QUANTITATIVE TRAIT; REVIEW; RNA INTERFERENCE; RNA SEQUENCE; STRUCTURE ACTIVITY RELATION; SYSTEMS BIOLOGY;

ALZHEIMER'S DISEASE; RNAI; SMALL MOLECULE SCREEN; SYSTEMS BIOLOGY; TARGETED PROTEOMICS;

ALZHEIMER DISEASE; CHRONIC DISEASE; DRUG DISCOVERY; GENOME-WIDE ASSOCIATION STUDY; HUMANS; MODELS, BIOLOGICAL;

EID: 84897954630     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2014.01.037     Document Type: Review

References (208)

1. L.E. Middleton, and K. Yaffe Promising strategies for the prevention of dementia Arch Neurol 66 2009 1210 1215
2. Z.S. Khachaturian, R.C. Petersen, S. Gauthier, N. Buckholtz, J.P. Corey-Bloom, and B. Evans et al. A roadmap for the prevention of dementia: the inaugural Leon Thal Symposium Alzheimers Dement 4 2008 156 163 (Pubitemid 351682266)
3. C. DeCarli, C. Kawas, J.H. Morrison, P.A. Reuter-Lorenz, R.A. Sperling, and C.B. Wright et al. Mechanisms of age-related cognitive change and targets for intervention: neural circuits, networks, and plasticity J Gerontol A: Biol Sci Med Sci 67 2012 747 753
4. L. Bertram, C.M. Lill, and R.E. Tanzi The genetics of Alzheimer disease: back to the future Neuron 68 2010 270 281
5. M.L. Daviglus, B.L. Plassman, A. Pirzada, C.C. Bell, P.E. Bowen, and J.R. Burke et al. Risk factors and preventive interventions for Alzheimer disease: state of the science Arch Neurol 68 2011 1185 1190
6. B.L. Plassman, J.W. Williams Jr., J.R. Burke, T. Holsinger, and S. Benjamin Systematic review: factors associated with risk for and possible prevention of cognitive decline in later life Ann Intern Med 153 2010 182 193
7. C. Purnell, S. Gao, C.M. Callahan, and H.C. Hendrie Cardiovascular risk factors and incident Alzheimer disease: a systematic review of the literature Alzheimer Dis Assoc Disord 23 2009 1 10
8. C. Reitz, C. Brayne, and R. Mayeux Epidemiology of Alzheimer disease Nat Rev Neurol 7 2011 137 152
9. P.B. Gorelick, A. Scuteri, S.E. Black, C. Decarli, S.M. Greenberg, and C. Iadecola et al. Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the American Heart Association/American Stroke Association Stroke 42 2011 2672 2713
10. G.M. McKhann, D.S. Knopman, H. Chertkow, B.T. Hyman, C.R. Jack Jr., and C.H. Kawas et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease Alzheimers Dement 7 2011 263 269
11. M.S. Albert, S.T. DeKosky, D. Dickson, B. Dubois, H.H. Feldman, and N.C. Fox et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease Alzheimers Dement 7 2011 270 279
12. R.A. Sperling, P.S. Aisen, L.A. Beckett, D.A. Bennett, S. Craft, and A.M. Fagan et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease Alzheimers Dement 7 2011 280 292
13. B.T. Hyman, C.H. Phelps, T.G. Beach, E.H. Bigio, N.J. Cairns, and M.C. Carrillo et al. National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease Alzheimers Dement 8 2012 1 13
14. A. Goate, and J. Hardy Twenty years of Alzheimer's disease-causing mutations J Neurochem 120 Suppl. 1 2012 3 8
15. E.M. Reiman, and W.J. Jagust Brain imaging in the study of Alzheimer's disease Neuroimage 61 2012 505 516
16. R. Sperling Potential of functional MRI as a biomarker in early Alzheimer's disease Neurobiol Aging 32 Suppl. 1 2011 S37 S43
17. R. Mayeux, and N. Schupf Blood-based biomarkers for Alzheimer's disease: plasma Aβ40 and Aβ42, and genetic variants Neurobiol Aging 32 Suppl. 1 2011 S10 S19
18. R.A. Sperling, C.R. Jack Jr., S.E. Black, M.P. Frosch, S.M. Greenberg, and B.T. Hyman et al. Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer's Association Research Roundtable Workgroup Alzheimers Dement 7 2011 367 385
19. J.L. Cummings Biomarkers in Alzheimer's disease drug development Alzheimers Dement 7 2011 e13 e44
20. J.Q. Trojanowski, H. Vandeerstichele, M. Korecka, C.M. Clark, P.S. Aisen, and R.C. Petersen et al. Update on the biomarker core of the Alzheimer's disease neuroimaging initiative subjects Alzheimers Dement 6 2010 230 238
21. C.R. Jack Jr., M.A. Bernstein, B.J. Borowski, J.L. Gunter, N.C. Fox, and P.M. Thompson et al. Update on the magnetic resonance imaging core of the Alzheimer's disease neuroimaging initiative Alzheimers Dement 6 2010 212 220
22. L. Warr, and Z. Walker Identification of biomarkers in Lewy-body disorders Q J Nucl Med Mol Imaging 56 2012 39 54
23. K.K. Johansen, L.R. White, S.B. Sando, and J.O. Aasly Biomarkers: Parkinson disease with dementia and dementia with Lewy bodies Parkinsonism Relat Disord 16 2010 307 315
24. A.V. Savonenko, T. Melnikova, A. Hiatt, T. Li, P.F. Worley, and J.C. Troncoso et al. Alzheimer's therapeutics: translation of preclinical science to clinical drug development Neuropsychopharmacology 37 January 2012 261 277
25. A. Corbett, J. Smith, and C. Ballard New and emerging treatments for Alzheimer's disease Expert Rev Neurother 12 2012 535 543
26. M. Sapra, and K.Y. Kim Anti-amyloid treatments in Alzheimer's disease Recent Pat CNS Drug Discov 4 2009 143 148
27. N. Herrmann, S.A. Chau, I. Kircanski, and K.L. Lanctôt Current and emerging drug treatment options for Alzheimer's disease: a systematic review Drugs 71 2011 2031 2065
28. H.J. Fu, B. Liu, J.L. Frost, and C.A. Lemere Amyloid-beta immunotherapy for Alzheimer's disease CNS Neurol Disord Drug Targets 9 2010 197 206
29. A. Boutajangout, E.M. Sigurdsson, and P.K. Krishnamurthy Tau as a therapeutic target for Alzheimer's disease Curr Alzheimer Res 8 2011 666 677
30. C. Ballard, Z. Kahn, and A. Corbett Treatment of dementia with Lewy bodies and Parkinson's disease dementia Drugs Aging 28 2011 769 777
31. B. De Strooper, R. Vassar, and T. Golde The secretases: enzymes with therapeutic potential in Alzheimer disease Nat Rev Neurol 6 2010 99 107
32. J. Rodda, and J. Carter Cholinesterase inhibitors memantine for symptomatic treatment of dementia BMJ 344 2012 e2986
33. P. Raina, P. Santaguida, A. Ismaila, C. Patterson, D. Cowan, and M. Levine et al. Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline Ann Intern Med 148 2008 379 397 (Pubitemid 351665469)
34. R.C. Green, L.S. Schneider, D.A. Amato, A.P. Beelen, G. Wilcock, and E.A. Swabb et al. Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial JAMA 302 2009 2557 2564
35. L. Lannfelt, K. Blennow, H. Zetterberg, S. Batsman, D. Ames, and J. Harrison et al. Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial Lancet Neurol 7 2008 779 786
36. B. Winblad, N. Andreasen, L. Minthon, A. Floesser, G. Imbert, and T. Dumortier et al. Safety, tolerability, and antibody response of active Aβ immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study Lancet Neurol 11 2012 597 604
37. M. Farlow, S.E. Arnold, C.H. van Dyck, P.S. Aisen, B.J. Snider, and A.P. Porsteinsson et al. Safety and biomarker effects of solanezumab in patients with Alzheimer's disease Alzheimers Dement 8 2012 261 271
38. G. Tong, J.S. Wang, O. Sverdlov, S.P. Huang, R. Slemmon, and R. Croop et al. Multicenter, randomized, double-blind, placebo-controlled, single-ascending dose study of the oral γ-secretase inhibitor BMS-708163 (Avagacestat): tolerability profile, pharmacokinetic parameters, and pharmacodynamic markers Clin Ther 34 2012 654 667
39. P.C. May, R.A. Dean, S.L. Lowe, F. Martenyi, S.M. Sheehan, and L.N. Boggs et al. Robust central reduction of amyloid-β in humans with an orally available, non-peptidic β-secretase inhibitor J Neurosci 31 2011 16507 16516
40. S. Salloway, R. Sperling, R. Keren, A.P. Porsteinsson, C.H. van Dyck, and P.N. Tariot et al. A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer disease Neurology 77 2011 1253 1262
41. C. Carlson, W. Estergard, J. Oh, J. Suhy, C.R. Jack Jr., and E. Siemers et al. Prevalence of asymptomatic vasogenic edema in pretreatment Alzheimer's disease study cohorts from phase 3 trials of semagacestat and solanezumab Alzheimers Dement 7 2011 396 401
42. A.S. Fleisher, R. Raman, E.R. Siemers, L. Becerra, C.M. Clark, and R.A. Dean et al. Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease Arch Neurol 65 2008 1031 1038
43. J.F. Quinn, R. Raman, R.G. Thomas, K. Yurko-Mauro, E.B. Nelson, and C. Van Dyck et al. Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial JAMA 304 2010 1903 1911
44. P.S. Aisen, L.S. Schneider, M. Sano, R. Diaz-Arrastia, C.H. van Dyck, and M.F. Weiner et al. High-dose B vitamin supplementation and cognitive decline in Alzheimer disease: a randomized controlled trial JAMA 300 2008 1774 1783
45. M. Sano, K.L. Bell, D. Galasko, J.E. Galvin, R.G. Thomas, and C.H. van Dyck et al. A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease Neurology 77 2011 556 563
46. J.C. Breitner, L.D. Baker, T.J. Montine, C.L. Meinert, C.G. Lyketsos, and K.H. Ashe et al. Extended results of the Alzheimer's disease anti-inflammatory prevention trial Alzheimers Dement 7 2011 402 411
47. M. Sano, D. Jacobs, H. Andrews, K. Bell, N. Graff-Radford, and J. Lucas et al. A multi-center, randomized, double blind placebo-controlled trial of estrogens to prevent Alzheimer's disease and loss of memory in women: design and baseline characteristics Clin Trials 5 2008 523 533
48. S. Craft, L.D. Baker, T.J. Montine, S. Minoshima, G.S. Watson, and A. Claxton et al. Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial Arch Neurol 69 2012 29 38
49. J.B. Langbaum, A.S. Fleisher, K. Chen, N. Ayutyanont, F. Lopera, and Y.T. Quiroz et al. Ushering in the study and treatment of preclinical Alzheimer disease Nat Rev Neurol 9 2013 371 381
50. R.A. Sperling, J. Karlawish, and K.A. Johnson Preclinical Alzheimer disease-the challenges ahead Nat Rev Neurol 9 2012 54 58
51. J.C. Morris, P.S. Aisen, R.J. Bateman, T.L. Benzinger, N.J. Cairns, and A.M. Fagan et al. Developing an international network for Alzheimer research: the dominantly inherited Alzheimer network Clin Investig (Lond) 2 2012 975 984
52. E. Giacobini, and G. Gold Alzheimer disease therapy-moving from amyloid-β to tau Nat Rev Neurol 2013 [epub]
53. K. Mullane, and M. Williams Alzheimer's therapeutics: continued clinical failures question the validity of the amyloid hypothesis - but what lies beyond? Biochem Pharmacol 85 2013 289 305
54. J.A. Pillai, and J.L. Cummings Clinical trials in predementia stages of Alzheimer disease Med Clin North Am 97 2013 439 457
55. C. Berk, and M.N. Sabbagh Successes and failures for drugs in late-stage development for Alzheimer's disease Drugs Aging 30 2013 783 792
56. K. Herrup, M.C. Carrillo, D. Schenk, A. Cacace, S. Desanti, and R. Fremeau et al. Beyond amyloid: getting real about nonamyloid targets in Alzheimer's disease Alzheimers Dement 9 2013 e1452 e1458
57. R.J. Castellani, and G. Perry Pathogenesis and disease-modifying therapy in Alzheimer's disease: the flat line of progress Arch Med Res 43 2012 694 698
58. D.M. Holtzman, E. Mandelkow, and D.J. Selkoe Alzheimer disease in 2020 Cold Spring Harb Perspect Med 1 November 2012 2
59. A.F. Teich, and O. Arancio Is the amyloid hypothesis of Alzheimer's disease therapeutically relevant? Biochem J 446 2012 165 177
60. R.F. Lane, D.W. Shineman, J.W. Steele, L.B. Lee, and H.M. Fillit Beyond amyloid: the future of therapeutics for Alzheimer's disease Adv Pharmacol 64 2012 213 271
61. Pharmaceutical Research, and Manufacturer's of America Alzheimer's research: setbacks and stepping stones 2012 http://phrma.org/sites/default/ files/1864/alzheimersetbacksreportfinal912.pdf
62. http://www.nia.nih.gov/announcements/2012/05/alzheimers-research-summit- may-14-15-2012.
63. http://projectreporter.nih.gov/project-info-description.cfm?aid= 8605315&icde=18360260&ddparam=&ddvalue=&ddsub=&cr= 13&csb=default&cs=ASC.
64. D.A. Bennett, J.A. Schneider, Z. Arvanitakis, and R.S. Wilson Overview and findings from the Religious Orders Study Curr Alzheimer's Res 9 2012 630 647
65. D.A. Bennett, J.A. Schneider, A.S. Buchman, L.L. Barnes, P.A. Boyle, and R.S. Wilson Overview and findings from the Rush Memory and Aging Project Curr Alzheimer's Res 9 2012 648 665
66. D.A. Bennett, R.S. Wilson, J.A. Schneider, D.A. Evans, L.A. Beckett, and N.T. Aggarwal et al. Natural history of mild cognitive impairment in older persons Neurology 59 2002 198 205 (Pubitemid 34779177)
67. D.A. Bennett, J.A. Schneider, N.T. Aggarwal, Z. Arvanitakis, R.C. Shah, and J.F. Kelly et al. Decision rules guiding the clinical diagnosis of Alzheimer's disease in two community-based cohort studies compared to standard practice in a clinic-based cohort study Neuroepidemiology 27 2006 169 176 (Pubitemid 44651437)
68. R.S. Wilson, L.A. Beckett, L.L. Barnes, J.A. Schneider, J. Bach, and D.A. Evans et al. Individual differences in rates of change in cognitive abilities of older persons Psychol Aging 17 2002 179 193 (Pubitemid 34568635)
69. R.S. Wilson, L.L. Barnes, K.R. Kreuger, G. Hoganson, J.L. Bienias, and D.A. Bennett Early and late life cognitive activity and cognitive systems in old age J Int Neuropsychol Soc 11 2005 400 407 (Pubitemid 41167177)
70. R.S. Wilson, J.A. Schneider, P.A. Boyle, S.E. Arnold, Y. Tang, and D.A. Bennett Chronic distress and incidence of mild cognitive impairment Neurology 68 2007 2085 2092 (Pubitemid 46912126)
71. R.S. Wilson, S.E. Leurgans, P.A. Boyle, and D.A. Bennett Cognitive decline in prodromal Alzheimer's disease and mild cognitive impairment Arch Neurol 68 2011 351 356
72. D.A. Bennett, J.A. Schneider, R.S. Wilson, J.L. Bienias, and S.E. Arnold Neurofibrillary tangles mediate the association of amyloid load and with clinical Alzheimer's disease and level of cognitive function Arch Neurol 61 2004 378 384 (Pubitemid 38327357)
73. J.A. Schneider, Z. Arvanitakis, S.E. Leurgans, and D.A. Bennett Neuropathology of probable AD and amnestic and non-amnestic MCI Ann Neurol 66 2009 200 208
74. Z. Arvanitakis, S.E. Leurgans, Z.B. Wang, R.S. Wilson, D.A. Bennett, and J.A. Schneider Cerebral amyloid angiopathy pathology in older persons with and without dementia Ann Neurol 69 2011 320 327
75. J.A. Schneider, Z. Arvanitakis, L. Yu, P.A. Boyle, S.E. Leurgans, and D.A. Bennett Cognitive impairment, decline, and fluctuations in older community-dwelling persons with Lewy bodies Brain 135 2012 3005 3014
76. D.A. Bennett, R.S. Wilson, P.A. Boyle, A.S. Buchman, and J.A. Schneider Relation of neuropathology to cognition in persons without cognitive impairment Ann Neurol 72 2012 5999 6609
77. A.S. Buchman, L. Yu, R.S. Wilson, J.A. Schneider, and D.A. Bennett Association of brain pathology with the progression of frailty in older adults Neurology 80 2013 2055 2061
78. A.S. Buchman, L. Yu, P.A. Boyle, S.R. Levine, S. Nag, and D.A. Schneider et al. Microvascular pathology and late-life motor impairment Neurology 80 2013 708 712
79. R.S. Wilson, L. Yu, J.Q.T. Trojanowski, E.Y. Chen, D.A. Bennett, and J.A. Schneider TDP-43 pathology, cognitive decline, and dementia in old age JAMA Neurol 2013 [epub]
80. P.A. Boyle, A.S. Buchman, R.S. Wilson, L. Yu, J.A. Schneider, and D.A. Bennett Effect of purpose in life on the relation between Alzheimer disease pathologic changes on cognitive function in advanced age Arch Gen Psychiatry 69 2012 499 504
81. P.A. Boyle, L. Yu, A.S. Buchman, and D.A. Bennett Risk aversion is associated with decision making among community-based older persons Front Psychol 3 2012 205
82. P.A. Boyle, L. Yu, R.S. Wilson, K. Gamble, A.S. Buchman, and D.A. Bennett Poor decision making is a consequence of cognitive decline among older persons without Alzheimer's disease or mild cognitive impairment PLoS ONE 7 2012 e43647
83. P.A. Boyle, L. Yu, E. Segawa, R.S. Wilson, A.S. Buchman, and D.A. Laibson et al. Association of cognition with temporal discounting in community based older persons BMC Geriatr 12 2012 48
84. R.S. Wilson, P.A. Boyle, S.R. Levine, L. Yu, S.E. Anagnos, and A.S. Buchman et al. Emotional neglect in childhood and cerebral infarction in old age Neurology 79 2012 1534 1539
85. A.S.P. Lim, A.M. Chang, J.M. Shulman, T. Raj, L.B. Chibnik, and A.J. Myers et al. A common polymorphism near PER1 and the timing of human behavioral rhythms Ann Neurol 72 2012 324 334
86. S.D. Han, A.S. Buchman, K. Arfanakis, D.A. Fleischman, and D.A. Bennett Functional connectivity networks associated with chronic musculoskeletal pain in old age Int J Geriatr Psychiatry 18 2012 39 48
87. R.S. Wilson, P.A. Boyle, E. Segawa, L. Yu, C.T. Begenyh, and S.E. Anagnos et al. The influence of cognitive decline on well-being in old age Psychol Aging 28 2013 304 313
88. R.S. Wilson, P.A. Boyle, L. Yu, L.L. Barnes, J.A. Schneider, and D.A. Bennett Life span cognitive activity, neuropathologic burden, and cognitive aging Neurology 81 2013 4314 4321
89. P.A. Boyle, L. Yu, K.J. Gamble, and D.A. Bennett Temporal discounting is associated with an increased risk of mortality among community-dwelling older persons without dementia PLoS ONE 8 2013 e67376
90. A. Weiss, A. Mirelman, A.S. Buchman, D.A. Bennett, N. Giladi, and J.M. Hausdorff Using a body-fixed sensor to identify subclinical gait difficulties in older adults with IADL disability: maximizing the output of the timed up and go PLoS ONE 8 2013 e68885
91. B.D. James, P.A. Boyle, and D.A. Bennett Correlates of susceptibility to scams in older adults without dementia J Elder Abuse Neglect 2013 [epub]
92. P.A. Boyle, L. Yu, R.S. Wilson, E. Segawa, A.S. Buchman, and D.A. Bennett Cognitive decline impairs health and financial literacy among community-based older persons without dementia Psychol Aging 28 2013 614 624
93. B.D. James, P.A. Boyle, L. Yu, and D.A. Bennett Internet use and decision making in community-based older persons Front Psychol 4 2013 605
94. S.D. Han, P.A. Boyle, L. Yu, D.A. Fleischman, D.A. Arfanakis, and D.A. Bennett Ventromedial PFC, parahippocampal, and cerebellar connectivity are associated with temporal discounting in old age Exp Gerontol 48 2013 1489 1498
95. A.S.P. Lim, M. Kowgier, L. Yu, A.S. Buchman, and D.A. Bennett Sleep modifies the relation of APOE to the risk of Alzheimer disease and neurofibrilliary tangle pathology JAMA Neurol 70 2013 1544 1551
96. R. Bove, E. Secor, L. Chibnik, L.L. Barnes, J.A. Schneider, and D.A. Bennett et al. Age at surgical menopause influences amyloid pathology and cognitive decline in older individuals Neurology 2013 [epub]
97. R.S. Wilson, P.A. Boyle, S.R. Levine, L. Yu, G.M. Hoganson, and A.S. Buchman et al. Harm avoidance and cerebral infarcts Neuropsychology 2013 [epub]
98. A.S. Buchman, S. Leurgans, A. Weiss, V. VanderHorst, A. Miralmen, and R. Dawe et al. Associations between quantitative mobility measures derived from components of conventional mobility testing and parkinsonian gait in older adults PLoS ONE 2014 [in press]
99. M.C. Morris, J.A. Schneider, K. Hensley, H. Li, C.C. Tangney, and S. Nag et al. Brain tocopherols related to Alzheimer disease neuropathology in humans Alzheimer's Dement 2014 [in press]
100. J.M. Shulman, L. Yu, A.S. Buchman, D.A. Evans, J.A. Schneider, and D.A. Bennett et al. Association of Parkinson's disease susceptibility loci with mild Parkinsonian signs in older persons JAMA Neurol 2014 [Epub ahead of print]
101. S. Bodovitz The neural correlate of consciousness J Theor Biol 254 2008 594 598
102. C.S. Carter, and V. van Veen Anterior cingulate cortex and conflict detection: an update of theory and data Cogn Affect Behav Neurosci 7 2007 367 379
103. L. Sorensen, P.J. Siddall, M.I. Trenell, and D.K. Yue Differences in metabolites in pain-processing brain regions in patients with diabetes and painful neuropathy Diabetes Care 31 2008 980 981
104. R.E. Jung, and R.J. Haier The Parieto-Frontal Integration Theory (P-FIT) of intelligence: converging neuroimaging evidence Behav Brain Sci 30 2007 135 154 (Pubitemid 47304539)
105. C. Amiez, and M. Petrides Selective involvement of the mid-dorsolateral prefrontal cortex in the coding of the serial order of visual stimuli in working memory Proc Natl Acad Sci USA 104 2007 13786 13791 (Pubitemid 350003398)
106. L.J. Murray, and C. Ranganath The dorsolateral prefrontal cortex contributes to successful relational memory encoding J Neurosci 27 2007 5515 5522 (Pubitemid 46790175)
107. R.B. Mars, and M.J. Grol Dorsolateral prefrontal cortex, working memory, and prospective coding for action J Neurosci 27 2007 1801 1802
108. R.S. Blumenfeld, and C. Ranganath Dorsolateral prefrontal cortex promotes long-term memory formation through its role in working memory organization J Neurosci 26 2006 916 925 (Pubitemid 43237084)
109. D.A. Lewis, and K. Mirnics Transcriptome alterations in schizophrenia: disturbing the functional architecture of the dorsolateral prefrontal cortex Prog Brain Res 158 2006 141 152 (Pubitemid 44486369)
110. U. Halsband, and R.K. Lange Motor learning in man: a review of functional and clinical studies J Physiol Paris 99 2006 414 424 (Pubitemid 43850801)
111. F.G. Hillary, H.M. Genova, N.D. Chiaravalloti, B. Rypma, and J. DeLuca Prefrontal modulation of working memory performance in brain injury and disease Hum Brain Mapp 27 2006 837 847 (Pubitemid 44684997)
112. F.M. Mottaghy Interfering with working memory in humans Neuroscience 139 2006 85 90
113. E. Hoshi Functional specialization within the dorsolateral prefrontal cortex: a review of anatomical and physiological studies of non-human primates Neurosci Res 54 2006 73 84 (Pubitemid 43112091)
114. H.R. Heekeren, S. Marrett, D.A. Ruff, P.A. Bandettini, and L.G. Ungerleider Involvement of human left dorsolateral prefrontal cortex in perceptual decision making is independent of response modality Proc Natl Acad Sci USA 103 2006 10023 10028 (Pubitemid 43993616)
115. M. Iacoboni Neural mechanisms of imitation Curr Opin Neurobiol 15 2005 632 637 (Pubitemid 41682303)
116. H.R. Naghavi, and L. Nyberg Common fronto-parietal activity in attention, memory, and consciousness: shared demands on integration? Conscious Cogn 14 2005 390 425 (Pubitemid 40799207)
117. S.A. Huettel, and J. Misiurek Modulation of prefrontal cortex activity by information toward a decision rule Neuroreport 15 2004 1883 1886 (Pubitemid 39180605)
118. J.M. Shulman, K. Chen, B.T. Keenan, L.B. Chibnik, A. Fleisher, and P. Thiyyagura et al. Genetic susceptibility for Alzheimer's disease neuritic plaque pathology JAMA Neurol 70 2013 1150 1157
119. P.L. De Jager, J.M. Shulman, L.B. Chibnik, B.T. Keenan, T. Raj, and R.S. Wilson et al. A genome-wide scan for common variants affecting rate of age-related cognitive decline Neurobiol Aging 33 2012 e11017-15
120. S. Purcell, B. Neale, K. Todd-Brown, L. Thomas, M.A. Ferreira, and D. Bender et al. PLINK: a tool set for whole-genome association and population-based linkage analyses Am J Hum Genet 81 2007 559 575 (Pubitemid 47330214)
121. A.L. Price, N.J. Patterson, R.M. Plenge, M.E. Weinblatt, N.A. Shadick, and D. Reich Principal components analysis corrects for stratification in genome-wide association studies Nat Genet 38 2006 904 909 (Pubitemid 44141658)
122. P.L. Jager, G. Srivastava, L.B. Chibnik, R.S. Wilson, J.A. Schneider, and D.A. Bennett Exploring the epigenetic architecture of cognitive resilience in aging: a DNA methylation and a genetic scan converge on several loci associated with resilience Association international conference Boston, MA, July 17, 2013 2013
123. L.B. Chibnik, L. Yu, B.T. Keenan, G. Srivastava, M.L. Eaton, and A. Meissner et al. The role of DNA methylation in Alzheimer's disease Annual meeting of the American society of human genetics Boston, MA, October 2013
124. B. Keenan, G.P. Srivastava, L.B. Chibnik, P. De Jager, D.A. Bennett, and J.A. Schneider An exploration of functional unit of DNA methylation in aging brain Alzheimers Dement 9 4 Suppl. 2013 172
125. L. Yu, G. Srivastava, L.B. Chibnik, M.L. Eaton, S. Leurgans, and J.A. Schneider et al. Global association of brain DNA methylation in AD susceptibility loci with pathologic AD diagnosis Annual meeting of the American Society of human genetics Boston, MA, October 2013
126. P.L. De Jager, and D.A. Bennett An inflection point in gene discovery efforts for neurodegenerative diseases: from syndromic diagnoses towards endophenotypes and the epigenome JAMA Neurol 70 2013 719 726
127. H. Li, J. Ruan, and R. Durbin Mapping short DNA sequencing reads and calling variants using mapping quality scores Genome Res 18 2008 1851 1858
128. A. McKenna, M. Hanna, E. Banks, A. Sivachenko, K. Cibulskis, and A. Kernytsky et al. The genome analysis toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data Genome Res 20 2001 1297 1303
129. Y. Zhang, T. Liu, C.A. Meyer, J. Eeckhoute, D.S. Johnson, and B.E. Bernstein et al. Model-based analysis of ChIP-Seq (MACS) Genome Biol 9 2008 R137
130. A.R. Quinlan, and I.M. Hall BEDTools: a flexible suite of utilities for comparing genomic features Bioinformatics 26 2010 841 842
131. S. Rajagopal, N. Pochet, G. Srivastava, L. Rosenkratz, C. McCabe, and D.A. Bennett et al. Characterizing the role of microRNA expression in the aging human brain transcriptome Association international conference Boston, MA, July 17, 2013 2013
132. N. Pochet, D. Borges-Rivera, B. Haas, S. Rajagopal, J. Xu, and C. McCabe et al. Characterizing the aging human brain transcriptome Annual meeting of the American society of human genetics Boston, MA, October 2013
133. J.Z. Levin, M. Yassour, X. Adiconis, C. Nusbaum, D.A. Thompson, and N. Friedman et al. Comprehensive comparative analysis of strand-specific RNA sequencing methods Nat Methods 7 2010 709 715
134. X. Adiconis, D. Borges-Rivera, R. Satija, D.S. DeLuca, M.A. Busby, and A.M. Berlin et al. Comparative analysis of RNA sequencing methods for degraded or low-input samples Nat Methods 10 2013 623 629
135. C.R. Jack Jr., D.S. Knopman, W.J. Jagust, L.M. Shaw, P.S. Aisen, and M.W. Weiner et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade Lancet Neurol 9 2010 119 128
136. R.S. Wilson, S.E. Leurgans, P.A. Boyle, J.A. Schneider, and D.A. Bennett Neurodegenerative basis of cognitive decline in old age Neurology 75 2010 1070 1078
137. P.A. Boyle, R.S. Wilson, L. Yu, A.M. Barr, W.G. Honer, and J.A. Schneider et al. Much of late life cognitive decline not due to common neuropathologies Ann Neurol 74 2013 478 489
138. P.A. Boyle, L. Yu, R.S. Wilson, J.A. Schneider, and D.A. Bennett Relation of neuropathology with cognitive decline among older persons without dementia Front Aging Neurosci 5 50 2013 1
139. L. Yu, P.A. Boyle, J.A. Schneider, E. Segawa, R.S. Wilson, and S. Leurgans et al. APOE ε4 Alzheimer's disease pathology, cerebrovascular disease, and cognitive change over the years prior to death Psychol Aging 2013 [epub]
140. L.B. Chibnik, J.M. Shulman, S.E. Leurgans, J.A. Schneider, R.S. Wilson, and D. Tran et al. CR1 is associated with amyloid plaque burden and age-related cognitive decline Ann Neurol 69 2011 560 569
141. L. Yu, J.M. Shulman, L. Chibnik, S. Leurgans, J.A. Schneider, and P.L. De Jager et al. The CETP I405V polymorphism is associated with an increased risk of Alzheimer's disease Aging Cell 11 2011 228 233
142. B.T. Keenan, J.M. Shulman, L.B. Chibnik, T. Raj, D. Tran, and M.R. Sabuncu et al. A coding variant in CR1 interacts with APOE-ε4 to influence cognitive decline Hum Mol Genet 15 2012 2377 2388
143. L. Yu, P.A. Boyle, S. Leurgans, J.A. Schneider, and D.A. Bennett Disentangling the effects of age and APOE on neuropathology and late life cognitive decline Neurobiol Aging 2013 [epub]
144. Y. Li, J.L. Bienias, and D.A. Bennett Confounding in the estimation of mediation effects Comput Stat Data Anal 51 2007 3173 3186 (Pubitemid 46188656)
145. Y. Li, J.A. Schneider, and D.A. Bennett Estimation of the mediation effect with a binary mediator Stat Med 26 2007 3398 3414 (Pubitemid 47161999)
146. H. Amieva, H. Jacqmin-Gadda, J.M. Orgogozo, N. Le Carret, C. Helmer, and L. Letenneur et al. The 9 year cognitive decline before dementia of the Alzheimer type: a prospective population-based study Brain 128 2005 1093 1101 (Pubitemid 40675464)
147. H. Amieva, M. Le Goff, X. Millet, J.M. Orgogozo, K. Pérès, and P. Barberger-Gateau et al. Prodromal Alzheimer's disease: successive emergence of the clinical symptoms Ann Neurol 64 2008 492 498
148. D.K. Johnson, M. Storandt, J.C. Morris, and J.E. Galvin Longitudinal study of the transition from healthy aging to Alzheimer disease Arch Neurol 66 2009 1254 1259
149. B.J. Small, and L. Bäckman Longitudinal trajectories of cognitive change in preclinical Alzheimer's disease: a growth mixture modeling analysis Cortex 43 2007 826 834 (Pubitemid 47517036)
150. E. Grober, C.B. Hall, R.B. Lipton, A.B. Zonderman, S.M. Resnick, and C. Kawas Memory impairment, executive dysfunction, and intellectual decline in preclinical Alzheimer's disease J Int Neuropsychol Soc 14 2008 266 278 (Pubitemid 351280005)
151. D.B. Howieson, N.E. Carlson, M.M. Moore, D. Wasserman, C.D. Abendroth, and J. Payne-Murphy et al. Trajectory of mild cognitive impairment onset J Int Neuropsychol Soc 14 2008 192 198 (Pubitemid 351279998)
152. J.E. Galvin, K.K. Powlishta, K. Wilkins, D.W. McKeel Jr., C. Xiong, and E. Grant et al. Predictors of preclinical Alzheimer disease and dementia: a clinicopathologic study Arch Neurol 62 2005 758 765 (Pubitemid 40656091)
153. R.C. Petersen, J.E. Parisi, D.W. Dickson, K.A. Johnson, D.S. Knopman, and B.F. Boeve et al. Neuropathologic features of amnestic mild cognitive impairment Arch Neurol 63 2006 665 672
154. J.A. Sonnen, E.B. Larson, P.K. Crane, S. Haneuse, G. Li, and G.D. Schellenberg et al. Pathological correlates of dementia in a longitudinal, population-based sample of aging Ann Neurol 62 2007 406 413 (Pubitemid 350105954)
155. P.T. Nelson, I. Alafuzoff, E.H. Bigio, C. Bouras, H. Braak, and N.J. Cairns et al. Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature J Neuropathol Exp Neurol 71 2012 362 381
156. J.A. Sonnen, N. Postupna, E.B. Larson, P.K. Crane, S.E. Rose, and K.S. Montine et al. Pathologic correlates of dementia in individuals with Lewy body disease Brain Pathol 20 2010 654 659
157. L. White, and L. Launer Relevance of cardiovascular risk factors and ischemic cerebrovascular disease to the pathogenesis of Alzheimer disease: a review of accrued findings from the Honolulu-Asia Aging Study Alzheimer Dis Assoc Disord 20 Suppl. 2 2006 S79 S83 (Pubitemid 44265856)
158. H. Dolan, B. Crain, J. Troncoso, S.M. Resnick, A.B. Zonderman, and R.J. Obrien Atherosclerosis, dementia, and Alzheimer disease in the Baltimore Longitudinal Study of Aging cohort Ann Neurol 68 2010 231 240
159. R.J. O'Brien, S.M. Resnick, A.B. Zonderman, L. Ferrucci, B.J. Crain, and O. Pletnikova et al. Neuropathologic studies of the Baltimore Longitudinal Study of Aging (BLSA) J Alzheimers Dis 18 2009 665 675
160. H. Petrovitch, G.W. Ross, Q. He, J. Uyehara-Lock, W. Markesbery, and D. Davis et al. Characterization of Japanese-American men with a single neocortical AD lesion type Neurobiol Aging 29 2008 1448 1455
161. L.J. Launer, H. Petrovitch, G.W. Ross, W. Markesbery, and L.R. White AD brain pathology: vascular origins? Results from the HAAS autopsy study Neurobiol Aging 29 2008 1587 1590
162. R. Au, S. Seshadri, K. Knox, A. Beiser, J.J. Himali, and H.J. Cabral et al. The Framingham Brain Donation Program: neuropathology along the cognitive continuum Curr Alzheimer Res 9 2012 673 686
163. M. Neumann, D.M. Sampathu, L.K. Kwong, A.C. Truax, M.C. Micsenyi, and T.T. Chou et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis Science 314 2006 130 133 (Pubitemid 44547757)
164. C. Amador-Ortiz, W.L. Lin, Z. Ahmed, D. Personett, P. Davies, and R. Duara et al. TDP-43 immunoreactivity in hippocampal sclerosis and Alzheimer's disease Ann Neurol 61 2007 435 445 (Pubitemid 46878771)
165. H. Nakashima-Yasuda, K. Uryu, J. Robinson, S.X. Xie, H. Hurtig, and J.E. Duda et al. Comorbidity of TDP-43 proteinopathy in Lewy body related diseases Acta Neuropathol 114 2007 221 229 (Pubitemid 47226148)
166. Z. Arvanitakis, J.L. Bienias, R.S. Wilson, D.A. Evans, and D.A. Bennett Diabetes and risk of Alzheimer's disease and decline in cognitive function Arch Neurol 61 2004 661 666 (Pubitemid 38637681)
167. Z. Arvanitakis, J.A. Schneider, R.S. Wilson, Y. Li, S.E. Arnold, and Z. Wang et al. Diabetes mellitus is related to cerebral infarction but not Alzheimer's disease pathology in older persons Neurology 67 2006 1960 1965 (Pubitemid 44967371)
168. R.S. Wilson, K.R. Krueger, S.E. Arnold, J.A. Schneider, J.F. Kelly, and L.L. Barnes et al. Loneliness and risk of Alzheimer disease Arch Gen Psychiatry 64 2007 234 240 (Pubitemid 46220781)
169. D.A. Bennett, P.L. De Jager, S.E. Leurgans, and J.A. Schneider Neuropathologic intermediate phenotypes enhance association to Alzheimer susceptibility alleles Neurology 72 2009 1495 1503
170. N. Ertekin-Taner, P.L. De Jager, L. Yu, and D.A. Bennett Alternative approaches in gene discovery and characterization in Alzheimer's disease Curr Genet Med Rep 1 2013 39 51
171. M.E. Blomqvist, K. Chalmers, N. Andreasen, N. Bogdanovic, G.K. Wilcock, and N.J. Cairns et al. Sequence variants of IDE are associated with the extent of betaamyloid deposition in the Alzheimer's disease brain Neurobiol Aging 26 2005 795 802 (Pubitemid 40249481)
172. M.B. McQueen, L. Bertram, C. Lange, K.D. Becker, M.S. Albert, and R.E. Tanzi et al. Exploring candidate gene associations with neuropsychological performance Am J Med Genet B: Neuropsychiatr Genet 144B 2007 987 991 (Pubitemid 350207770)
173. R.J. Caselli, A.C. Dueck, M.J. Huentelman, M.W. Lutz, A.M. Saunders, and E.M. Reiman et al. Longitudinal modeling of cognitive aging and the TOMM40 effect Alzheimers Dement 8 2012 490 495
174. R.J. Caselli, A.C. Dueck, D. Osborne, M.N. Sabbagh, D.J. Connor, and G.L. Ahern et al. Longitudinal modeling of age-related memory decline and the APOE epsilon4 effect N Engl J Med 361 2009 255 263
175. W.L.A. Fung, M.G. Naylor, D.A. Bennett, C. Lange, and D. Blacker Principal components methods for narrow-sense heritability in the analysis of multidimensional longitudinal cognitive phenotypes Am J Med Genet B: Neuropsychiatr Genet 162 2013 770 778
176. J.M. Shulman, L. Chibnik, C. Aubin, J.A. Schneider, D.A. Bennett, and P.L. De Jager Intermediate phenotypes identify divergent pathways Alzheimer's disease PLoS ONE 5 June 2010 e11244
177. J.M. Shulman, P. Chipendo, C. Aubin, P. Kramer, J.A. Schneider, and D.A. Bennett et al. Functional screening of Alzheimer pathology genome-wide association signals in Drosophila Am J Hum Genet 88 2011 232 238
178. S. Treusch, S. Hamamichi, J.L. Goodman, K.E. Matlack, C.Y. Chung, and V. Baru et al. Functional links in yeast between Aβ toxicity, endocytic trafficking and Alzheimer's disease risk factors Science 334 2011 1241 1245
179. D. Tsuang, J.B. Leverenz, O.L. Lopez, R.L. Hamilton, D.A. Bennett, and J.A. Schneider et al. GBA mutations increase risk for Lewy body disease with and without Alzheimer's disease pathology Neurology 79 2012 1944 1950
180. R. Sherva, Y. Tripodis, D.A. Bennett, L.B. Chibnik, P.K. Crane, and P.L. De Jager et al. Genome-wide association study of the rate of cognitive decline in Alzheimer's disease Alzheimer's Dement. 2013 [epub]
181. R.S. Wilson, J.A. Schneider, L.L. Barnes, L.A. Beckett, N.T. Aggarwal, and E.J. Cochran et al. The apolipoprotein E ε4 allele and decline in different cognitive systems over a 6-year period Arch Neurol 59 2002 1154 1160 (Pubitemid 34755829)
182. R.S. Wilson, J.L. Bienias, E. Berry-Kravis, D.A. Evans, and D.A. Bennett The apolipoprotein E ε2 allele and decline in episodic memory J Neurol Neurosurg Psychiatry 73 2002 672 677 (Pubitemid 35448851)
183. D.A. Bennett, J.A. Schneider, R.S. Wilson, J.L. Bienias, E. Berry-Kravis, and S.E. Arnold Amyloid mediates the association of apolipoprotein E ε4 to level of cognitive function in older persons J Neurol Neurosurg Psychiatry 76 2005 1194 1199 (Pubitemid 41208366)
184. L.L. Barnes, Z. Arvanitakis, L. Yu, J. Kelly, P.L. De Jager, and D.A. Bennett et al. and change in episodic memory in blacks and whites Neuroepidemiology 40 2013 211 219
185. D.E. Schmechel, A.M. Saunders, W.J. Strittmatter, B.J. Crain, C.M. Hulette, and S.H. Joo et al. Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease Proc Natl Acad Sci USA 90 1993 9649 9653 (Pubitemid 23315843)
186. B. Zhang, C. Gaiteri, L.-G. Bodea, Z. Wang, J. McElwee, and A.A. Podtelezhnikov et al. Integrated systems approach identifies genetic nodes and networks in late-onset Alzheimer's disease Cell 153 2013 707 720
187. T. Raj, J.M. Shulman, B.T. Keenan, L.B. Chibnik, D.A. Evans, and D.A. Bennett et al. Alzheimer disease susceptibility loci: evidence for a protein network under natural selection Am J Hum Genet 90 2012 720 726
188. T. Shi, T.L. Fillmore, X. Sun, R. Zhao, A.A. Schepmoes, and M. Hossain et al. Antibody-free, targeted mass-spectrometric approach for quantification of proteins at low picogram per milliliter levels in human plasma/serum Proc Natl Acad Sci USA 109 2012 15395 15400
189. T. Shi, D. Su, T. Liu, D.G. Camp 2nd, W.J. Qian, and R.D. Smith Advancing the sensitivity of selected reaction monitoring-based targeted quantitative proteomics Proteomics 12 2012 1074 1092
190. S. Gallien, E. Duriez, and B. Domon Selected reaction monitoring applied to proteomics J Mass Spectrom 46 2011 298 312
191. P. Picotti, B. Bodenmiller, L.N. Mueller, B. Domon, and R. Aebersold Full dynamic range proteome analysis of S. cerevisiae by targeted proteomics Cell 138 August 2009 795 806
192. C. Karlsson, L. Malmstrom, Aebersold, and J. Malmstrom Proteome-wide selected reaction monitoring assays for the human pathogen Streptococcus pyogenes Nat Commun 3 December 2012 1301
193. M. Hossain, D.T. Kaleta, E.W. Robinson, T. Liu, R. Zhao, and J.S. Page et al. Enhanced sensitivity for selected reaction monitoring mass spectrometry-based targeted proteomics using a dual stage electrodynamic ion funnel interface Mol Cell Proteomics 10 2011 M000062-MCP201
194. I. Amit, M. Garber, N. Chevrier, A.P. Leite, Y. Donner, and T. Eisenhaure et al. Unbiased reconstruction of a mammalian transcriptional network mediating pathogen responses Science 326 2009 257 263
195. N. Chevrier, P. Mertins, M.N. Artyomov, A.K. Shalek, M. Iannacone, and M.F. Ciaccio et al. Systematic discovery of TLR signaling components delineates viral-sensing circuits Cell 147 2011 853 867
196. S. Dandapani, and L.A. Marcaurelle Current strategies for diversity-oriented synthesis Curr Opin Chem Biol 14 2010 362 370
197. T. Wyss-Coray, and J. Rogers Inflammation in Alzheimer disease-a brief review of the basic science and clinical literature Cold Spring Harb Perspect Med 2 2013 a006346
198. E.M. Bradshaw, L.B. Chibnik, B.T. Keenan, L. Ottoboni, T. Raj, and A. Tang et al. CD33 Alzheimer's disease locus: altered monocyte function and amyloid biology Nat Neurosci 16 2013 848 850
199. T. Raj, K.J. Ryan, J.M. Replogle, L.B. Chibnik, L. Rosenkrantz, and A. Tang et al. CD33: increased inclusion of exon 2 implicates the Ig V-set domain in Alzheimer's disease susceptibility Hum Mol Genet 2013 [epub]
200. W.L. Klein Synaptotoxic amyloid-β oligomers: a molecular basis for the cause, diagnosis, and treatment of Alzheimer's disease? J Alzheimers Dis 33 Suppl. 1 2013 S49 S65
201. K.H. Ashe, and K.R. Zahs Probing the biology of Alzheimer's disease in mice Neuron 66 2010 631 645
202. S.E. Lesné, M.A. Sherman, M. Kuskowski, J.A. Schneider, D.A. Bennett, and K.H. Ashe Brain amyloid-β oligomers in aging and Alzheimer's disease Brain 136 2013 1383 1398
203. C. Tremblay, M. Pilote, A. Phivilay, V. Emond, D.A. Bennett, and F. Calon Biochemical characterization of Aβ and tau pathologies in persons with mild cognitive impairment and Alzheimer disease J Alzheimer's Dis 12 2007 377 390
204. M. Larson, M.A. Sherman, M. Kuskowski, J.A. Schneider, D.A. Bennett, and S.E. Lesné Soluble α-synuclein, is a novel modulator of Alzheimer's disease pathophysiology J Neurosci 32 2012 10253 10266
205. V.H. Perry Contribution of systemic inflammation to chronic neurodegeneration Acta Neuropathol 120 September (3) 2010 277 286
206. D.J. Bonda, X. Wang, G. Perry, A. Nunomura, M. Tabaton, and X. Zhu et al. Oxidative stress in Alzheimer disease: a possibility for prevention Neuropharmacology 59 2010 290 294
207. R.A. Nixon The role of autophagy in neurodegenerative disease Nat Med 19 2013 983 997
208. B.S. Appleby, and J.L. Cummings Discovering new treatments for Alzheimer's disease by repurposing approved medications Curr Top Med Chem 13 2013 2306 2327